Arrowhead Pharmaceuticals (ARWR) Reports Fiscal 2026 Results as Commercial Transition Accelerates

Key Takeaways

• Arrowhead Pharmaceuticals reported fiscal 2026 revenue of $450.82 million, down 46% from $829.45 million a year earlier, reflecting the absence of large prior-year collaboration payments.
• Full-year net loss per share widened to $5.11 (GAAP), missing consensus estimates, driven largely by a $215 million acquired Priority Review Voucher and higher research and development spending.
• REDEMPLO (plozasiran), the company's first approved medicine for familial chylomicronemia syndrome (FCS), showed strong launch momentum, with new-to-brand prescriptions up 63% quarter over quarter.
• Arrowhead submitted a supplemental New Drug Application to the FDA for plozasiran in severe hypertriglyceridemia (SHTG) and was accepted into the FDA's Split Real Time Application Review (STAR) pilot program, positioning a potential U.S. launch in the second quarter of 2027.
• The company refinanced its credit facility with a lower-cost $400 million term loan and ended the fiscal year with $1.19 billion in total cash resources.

Earnings Context and Why It Matters

Arrowhead Pharmaceuticals is at a pivotal transition point, moving from a clinical-stage developer of RNA interference (RNAi) therapies into a fully commercial biopharmaceutical company. Fiscal 2026 marked the first full year of REDEMPLO's U.S. launch following its FDA approval in November 2025, making this report a critical measure of the company's commercial execution. The results also carry significance because Arrowhead is aggressively expanding REDEMPLO's label toward a much larger severe hypertriglyceridemia population. At the same time, a widening net loss and a planned change in the company's fiscal year end highlight the costs and operational shifts underway. For investors, the report offers a clearer picture of whether commercial traction can eventually offset escalating research and development investment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Reported Results

Arrowhead Pharmaceuticals reported fiscal 2026 results for the year ended September 30, 2026. Full-year revenue totaled $450.82 million, a 46% decline from $829.45 million in fiscal 2025 and slightly below the roughly $464 million analyst consensus. The prior year benefited from a large upfront payment tied to a collaboration agreement, which did not repeat. On the bottom line, the company posted a GAAP (Generally Accepted Accounting Principles) net loss of $5.11 per diluted share, materially wider than the consensus estimate of a roughly $3.51 loss.

The deeper loss was driven in part by a $215 million charge for an acquired Priority Review Voucher, along with increased operating expenses. Research and development spending rose to $739.14 million, while selling, general, and administrative expenses climbed to $202.05 million as the company scaled its commercial operations. Despite the wider loss, management emphasized REDEMPLO's launch progress, noting new-to-brand prescriptions grew 63% quarter over quarter, cumulative prescriptions reached 950 by quarter-end, and more than 640 unique practitioners had prescribed the therapy.

Market Reaction and Investor Sentiment

Shares of ARWR declined roughly 2.4% in after-hours trading following the report, as investors weighed the wider-than-expected GAAP loss and slightly lower revenue against encouraging REDEMPLO momentum. The market's relatively measured response suggests sentiment is balancing near-term profitability concerns against the company's longer-term commercial and pipeline opportunity. The $215 million Priority Review Voucher charge was a notable one-time factor that inflated the reported loss, which may have softened the negative reaction. Still, the sequential revenue decline and continued heavy spending remain central concerns for shareholders, while the REDEMPLO prescription trajectory and the pending severe hypertriglyceridemia expansion serve as key sources of optimism.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central catalyst for Arrowhead is the regulatory pathway for plozasiran in severe hypertriglyceridemia. The company has submitted a supplemental New Drug Application and secured entry into the FDA's STAR pilot program, which provides a six-month priority review. Management is preparing for a potential U.S. launch in the second quarter of 2027, and investors will closely track any updates on approval timing and payer discussions.

REDEMPLO's commercial trajectory in its currently approved FCS indication remains another key monitor. Prescription growth, the number of active prescribers, and patient support program uptake will indicate whether the launch can build durable revenue. Investors should also watch expense trends, since rising research and development costs continue to pressure the bottom line even as collaboration and milestone revenue fluctuates from quarter to quarter.

Finally, Arrowhead announced a change in its fiscal year end from September 30 to December 31, effective January 1, 2027, which will require a transition report for the three-month period ending December 31, 2026. This shift means future reporting periods and comparisons will be structured differently, and investors should monitor how the company communicates results during the transition. The refinanced $400 million term loan at a lower interest rate and the $1.19 billion cash position provide a degree of financial runway, but continued commercial execution and pipeline milestones will be essential to sustaining investor confidence. From what I see, the cash position gives the company some breathing room as it executes on these plans.

Using Tickeron Tools for Deeper Analysis

In my own research process, I often turn to Tickeron’s AI Screener when evaluating names like ARWR. It helps filter for technical patterns, fundamentals, and AI-driven signals across the biopharma space, allowing for quicker comparisons to peers and identification of potential setups. This kind of tool has become a regular part of how I cross-check earnings implications and sector trends without relying solely on manual review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume